Prof. Didier Merlin

Georgia State University, USA

Email: [email protected]

Qualifications

1994 Ph.D., Cell Biology, University Paris VII, France

1989 M.S., Cell Biology, University Paris VII, France

Publications (Selected)

1. Mow, R. J., Shi, X. D., Lu, W., et al. (2026). Oral Colon-Targeted Lipid Nanoparticles Enhance Upadacitinib Delivery and Efficacy in a Murine Model of Ulcerative Colitis. International Journal of Molecular Sciences, 27(9), 3758.
2. Pirzada, M., Ekanayake, S. H., Kattel, A., et al. (2026). Monitoring Biomolecular Changes During Colitis Progression Using Infrared Spectroscopy in Dextran Sodium Sulfate-Treated Mouse Serum. Journal of Biophotonics, 19(3), e70235.
3. Casado-Bedmar, M., Roy, M., Berthet, L., et al. (2024). Fecal let-7b and miR-21 directly modulate the intestinal microbiota, driving chronic inflammation. Gut Microbes, 16(1), 2394249.
4. Mow, R. J., Kuczma, M. P., Shi, X. D., et al. (2024). Harnessing a Safe Novel Lipid Nanoparticle: Targeted Oral Delivery to Colonic Epithelial and Macrophage Cells in a Colitis Mouse Model. Nanomaterials, 14(22), 1800.
5. Liu, J. H., Yang, C. H., Merlin, D., et al. (2024). Hyaluronic acid-functionalized nanoparticles for ulcerative colitis-targeted therapy: a comparative study of oral administration and intravenous injection. Biomaterials Science, 12(22), 5834–5844.
6. Yang, C. H., Sharma, K., Mow, R. J., et al. (2024). Unleashing the Potential of Oral Deliverable Nanomedicine in the Treatment of Inflammatory Bowel Disease. Cellular and Molecular Gastroenterology and Hepatology, 18(2), 101333.
7. Yang, C. H., & Merlin, D. (2024). Unveiling Colitis: A Journey through the Dextran Sodium Sulfate-induced Model. Inflammatory Bowel Diseases, 30(5), 844–853.
8. Long, D. P., Alghoul, Z., Sung, J., et al. (2023). Prevention of Colitis-Associated Cancer via Oral Administration of M13-Loaded Lipid Nanoparticles. Pharmaceutics, 15(9), 2331.
9. Long, D. P., Alghoul, Z., Sung, J. S., et al. (2023). Oral administration of M13-loaded nanoliposomes is safe and effective to treat colitis-associated cancer in mice. Expert Opinion on Drug Delivery, 20(10), 1443–1462.
10. Yang, C. H., & Merlin, D. (2023). Challenges to Safe Nanomedicine Treatment. Nanomaterials, 13(7), 1171.
11. Yang, C. H., Alpini, G., Glaser, S., et al. (2022). Lipid nanoparticles for oral delivery of nucleic acids for treating inflammatory bowel disease. Nanomedicine, 17(21), 1501–1504.
12. Sung, J. S., Alghoul, Z., Long, D. P., et al. (2022). Oral delivery of IL-22 mRNA-loaded lipid nanoparticles targeting the injured intestinal mucosa: A novel therapeutic solution to treat ulcerative colitis. Biomaterials, 288, 121707.
13. Alghoul, Z., Yang, C. H., & Merlin, D. (2022). The Current Status of Molecular Biomarkers for Inflammatory Bowel Disease. Biomedicines, 10(7), 1492.
14. Yang, C. H., Sung, J., Long, D. P., et al. (2022). Prevention of Ulcerative Colitis by Autologous Metabolite Transfer from Colitogenic Microbiota Treated with Lipid Nanoparticles Encapsulating an Anti-Inflammatory Drug Candidate. Pharmaceutics, 14(6), 1233.
15. Liu, D. D., Saikam, V., Skrada, K. A., et al. (2022). Inflammatory bowel disease biomarkers. Medicinal Research Reviews, 42(5), 1856–1887.
16. Sung, J., Alghoul, Z., Long, D. P., et al. (2022). Oral delivery of IL-22 mRNA-loaded lipid nanoparticles targeting IL-22 protein to the injured intestinal mucosa: A potential therapeutic solution to treat ulcerative colitis. Gastroenterology, 162(7), S406–S406.
17. Ghimire, H., Viennois, E., Hu, X. J., et al. (2022). Infrared spectrometric biomarkers for ulcerative colitis screening using human serum samples. Journal of Biophotonics, 15(6), e202100307.
18. Long, D. P., Yang, C. H., Alghoul, Z., et al. (2022). Oral administration of nanoliposomes loaded M13 may treat ulcerative colitis and colitis-associated cancer without causing any side effects. Gastroenterology, 162(3), S6–S7.
19. Long, D. P., Yang, C. H., Alghoul, Z., et al. (2022). Oral administration of nanoliposomes loaded M13 may treat ulcerative colitis and colitis-associated cancer without causing any side effects. Inflammatory Bowel Diseases, 28, S6–S7.
20. Duan, L., Zheng, F., Merlin, D., et al. (2021). Editorial: Oral Nanotherapeutics for Colon Diseases. Frontiers in Bioengineering and Biotechnology, 9, 816304.

Profile Details
https://scholar.google.com/citations?user=iirGxtEAAAAJ&hl=en
https://biomedical.gsu.edu/profile/didier-merlin/
https://www.researchgate.net/profile/Didier-Merlin

WOS ResearcherID: JSD-2931-2023